News
30.05.16
Strimvelis receives European marketing authorisation to treat very rare disease, ADA-SCID
GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) today announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID
01.04.16
GSK receives positive CHMP opinion in Europe for StrimvelisTM, the first gene therapy to treat very rare disease, ADA-SCID
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Strimvelis
16.06.14
Gene therapy: a "molecular scalpel" corrects the genes of blood stem cells
A group of researchers at the San Raffaele Telethon Institute for Gene Therapy (TIGET) in Milan was able for the first time to rewrite the DNA of human blood stem cells by editing the genome.
16.06.14
Cardiomyopathies: a protein has been discovered that keeps the heart young
It's called Atrogin-1 and it's a protein that plays an important role in cardiac health: its task, as demonstrated by a study funded by Telethon, is to identify and dispose of the waste substances produced by cellular activity, which would be harmful to the heart.
10.02.14
Towards success
Up to June 30, 2013, the Telethon Foundation has invested over € 394 million to fund 2470 research projects, which have yielded 9350 articles in international scientific journals.
10.02.14
Ipex syndrome: fresh hope for a cure from Telethon - San Raffaele researchers
From Telethon - San Raffaele research come new treatment prospects for a rare genetic diseases affecting the immune system, IPEX syndrome.
14.01.14
From Telethon-funded gene therapy comes a new weapon in the battle against cancer
The innovative technique developed in the laboratories of the Telethon San Raffaele Institute for Gene Therapy for the treatment of two extremely serious genetic diseases can also be effective in treating tumours.
14.01.14
TIGEM: a centre of excellence for the south
The new premises of the Telethon Institute for Genetics and Medicine (Tigem) is set to open in the former "Olivetti area" in Pozzuoli.
06.11.13
Research into a rare kidney disease reveals a mechanism responsible for hypertension
Research into a rare kidney disease has shed important light on a possible way to tackle high blood pressure, a risk factor for the circulatory system that in Italy alone affects a third of the adult population.
